On July 7, 2025, HC Wainwright & Co., led by analyst Swayampakula Ramakanth, released new coverage on Aethlon Medical (AEMD, Financial). The firm has set a price target of $1.50 USD for AEMD. This marks the initiation of coverage, as there was no prior price target.
The current rating for Aethlon Medical (AEMD, Financial) is set as "Neutral." This rating indicates a balanced view from the analyst, who does not currently foresee significant upward or downward movement in the stock price.
Investors looking at Aethlon Medical (AEMD, Financial) should consider this new information from HC Wainwright & Co. in their decision-making process as the company continues to evolve within the medical field.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Aethlon Medical Inc (AEMD, Financial) is $4.55 with a high estimate of $4.55 and a low estimate of $4.55. The average target implies an upside of 288.89% from the current price of $1.17. More detailed estimate data can be found on the Aethlon Medical Inc (AEMD) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Aethlon Medical Inc's (AEMD, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Aethlon Medical Inc (AEMD, Financial) in one year is $98.68, suggesting a upside of 8334.19% from the current price of $1.17. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Aethlon Medical Inc (AEMD) Summary page.
